Results from a phase 1 study of nusinersen (ISIS-SMN _Rx ) in children with spinal muscular atrophy

Abstract

Objective: To examine safety, tolerability, pharmacokinetics, and preliminary clinical efficacy of intrathecal nusinersen (previously ISIS-SMN Rx ), an antisense oligonucleotide designed to alter splicing of SMN2 mRNA, in patients with childhood spinal muscular atrophy (SMA).